A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 612 participants.
Also called NCT01473407
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 612 participants
- Registry
-
NCT01473407
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT01473407. Randomized; quadruple masking; primary purpose treatment. Start 2012-01-31 (actual); primary completion 2014-02-11 (actual). Results posted on 2018-07-13.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
- Acronym
- AiME - 01
- Condition
- Chronic Kidney Disease
- Condition
- Chronic Renal Failure
- Intervention (Biological)
- Epoetin Hospira
- Intervention (Biological)
- Epogen (Amgen)
- Lead sponsor
- Pfizer
- Collaborator
- Hospira, now a wholly owned subsidiary of Pfizer
Record details
- Record id
cardio:ct-nct01473407- Content hash
96e32a4d0466cb2bf5ad5f9bad55e37b0699453d1c339309fe5661198b21cb8f